Solesence, Inc. Common Stock

Solesence, Inc. Common Stock

SLSN
Solesence, Inc. Common StockUS flagNASDAQ Global Select
0.78
USD
-0.01
- -
54.74MMarket Cap
Solesence, Inc. Common Stock
SLSN
(NASDAQ Global Select)

Recent

price

0.78

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
0.45
0.46
0.41
0.34
0.35
0.36
0.35
0.4
0.42
0.34
0.45
0.65
0.76
0.75
0.84
0.88
0.86
Revenue per Share
-0.19
-0.16
-0.1
-0.09
-0.06
-0.04
-0.04
-0.03
-0.06
-0.08
0.03
0.05
-0.05
-0.09
0.07
0.03
0.01
Basic EPS, GAAP
-0.08
-0.14
-0.03
-0.03
-0.05
-0.02
-0.01
-0.04
-0.04
-0.1
-0.08
0.01
-0.09
-0.06
-0.04
-0.15
-0.02
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
-3.88
-4.04
-3.59
-3.18
-3.23
-3.27
-3.06
-3.04
-2.88
-2.74
-2.6
-2.15
-2.03
-2.1
-1.6
-1.39
-1.4
Book Value per Share
0.49
0.35
0.31
0.19
0.14
0.1
0.09
0.1
0.04
0.04
0.07
0.17
0.12
0.04
0.24
0.25
0.24
Tangible Book Value per Share
21
21
24
28
28
29
31
31
34
37
38
45
49
50
62
70
70
Basic Weighted Avg Shares
9
10
10
10
10
10
11
12
14
13
17
29
37
37
52
62
60
Sales/Revenue/Turnover
-43.34
-34.85
-23.8
-25.97
-17.33
-11.42
-11.76
-6.19
-14.25
-22.35
8.67
8.68
-6.05
-9.51
9.8
2.53
1.34
Operating Margin (%)
1
1
1
1
1
1
1
- -
- -
- -
- -
- -
1
1
1
1
1
Depreciation Expense
-4
-3
-2
-2
-2
-1
-1
-1
-2
-3
1
2
-3
-4
4
2
1
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
1.57
- -
- -
5.09
3.92
7.18
Effective Tax Rate (%)
-43.1
-34.85
-23.84
-25.84
-17.38
-11.56
-11.9
-6.33
-14.66
-24.03
5.78
7.87
-7.03
-11.77
8.09
2.88
1.56
Profit Margin (%)
6
5
5
4
3
2
2
3
1
1
2
4
3
1
4
15
14
Working Capital
- -
- -
- -
- -
- -
- -
- -
- -
1
3
4
13
14
15
9
18
18
LT Debt
10
7
8
5
4
3
3
3
1
2
3
7
6
2
15
18
17
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
17.73
15.52
- -
- -
18.59
4.28
2
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
-1.59
-3.97
- -
- -
-5.82
-3.4
-2.46
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)

Capital Structure

FRC

in mil. unless spec.
Sep'25
Dec'25
Mar'26
ST Debt
7
6
4
LT Borrowings
10
10
10
LT Finance Leases
8
8
7
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
71
71
71
Market Capitalization
226
113
67

Working Capital

FRC

in mil. unless spec.
Sep'25
Dec'25
Mar'26
Total Current Assets
33
29
26
Cash, Cash Equivalents & STI
- -
1
1
Accounts Receivable, Net
10
7
6
Inventories
19
19
18
Total Current Liabilities
18
14
13
Payables & Accruals
10
7
7
ST Debt
7
6
4
Deferred Revenue
1
1
1

Growth Rates

FRC

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
83.25%
157.27%
17.98%
Free Cash Flow
-63.79%
-189.78%
313.99%
Net Income, GAAP
-22.09%
-53.06%
-57.73%
Sales/Revenue/Turnover
21.66%
31.52%
18.56%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
10
13
17
13
52
2025
15
20
15
12
62
2026
13
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.02
0.02
0.04
-0.01
0.07
2025
- -
0.04
-0.02
- -
0.03
2026
-0.01
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Business
Solesence, Inc. develops, manufactures, and sells mineral-based skin health solutions and engineered materials for the beauty and life science industries. The company provides proprietary Active Stress Defense technology platform, including Original Active Stress Defense and award-winning Kleair; skin care formulations with non-nano mineral UV protection as active pharmaceutical ingredients; sunscreens and daily skin care products; complexion and color cosmetics; white label, white label+, and full custom development services; surface-engineered zinc oxide and titanium dioxide; and advanced materials such as architectural coatings, industrial coatings, abrasion-resistant additives, plastics additives, and medical diagnostics applications. Solesence, Inc. operates primarily in the United States from its headquarters in Romeoville, Illinois, where it was incorporated in 1989; it serves global beauty brands across prestige, mass, and EU markets through its wholly owned subsidiary Solesence, LLC. In March 2025, the company changed its name from Nanophase Technologies Corporation to reflect its focus on skin health innovation; it reported record 2024 revenue of $52.3 million, up 40% year-over-year, with expanded production capacity at its Bolingbrook facility to support over $200 million in annual consumer products revenue; launched over two dozen new SKUs; initiated a NASDAQ uplisting process; appointed a dedicated Chief Financial Officer; and earned awards including the 2025 Cosmetics & Toiletries Allē Award for Au Lait Face Milk SPF 50+ featuring Kleair technology.

Company News

APIChatGPT
  • SLSN Unveils Two Scalp Care Products Using Patented Technology

  • Solésence Brings Patent-Backed Skin Health Innovation to Hair and Scalp

  • Solésence Named Contract Manufacturing Partner of the Year in the 2026 Cosmetics Business Innovation Awards

  • Solésence Day Mode Hero Concealer SPF 50+ Wins Three Categories at the 2026 Cosmetics & Toiletries Allē Awards, Marking Fourth Year of Recognition

  • Solésence Day Mode Hero Concealer SPF 50+ Wins Three Categories at the 2026 Cosmetics & Toiletries Allē Awards, Marking Fourth Year of Recognition

  • SLSN Incurs Q1 Loss Due to Shipment Delays, High Operating Costs

  • Solésence Supports Landmark Report on UV Safety in the United Kingdom as Member of UV Safety Coalition

  • Solesence, Inc. (SLSN) Q1 2026 Earnings Call Transcript

  • Solésence Reports First Quarter 2026 Financial Results

  • Solésence Launches New Skin Health Technologies: WHSPR™ and Chromalüm™

  • Solésence To Report First Quarter 2026 Financial Results and Host a Conference Call on May 12

  • Solésence, Inc. Announces Appointment of New Independent Director

  • Zacks Initiates Coverage of SLSN With Underperform Recommendation

  • Solesence, Inc. (SLSN) Q4 2025 Earnings Call Transcript

  • Solésence Reports Fourth Quarter and Full-Year 2025 Financial Results

  • Solésence To Report Fourth Quarter and Full Year 2025 Financial Results and Host a Conference Call on March 31, 2026

  • Reviewing Solesence (NASDAQ:SLSN) and Rejuvel Bio-Sciences (OTCMKTS:NUUU)

  • Yoolie Park joins Solésence, Inc. as Vice President of Brand Partnerships

  • Solesence (NASDAQ:SLSN) Stock Price Up 2% – Time to Buy?

  • Solesence, Inc. (SLSN) Q3 2025 Earnings Call Transcript